Afya Limited Releases 2025 Integrated Report

BELO HORIZONTE, Brazil--(BUSINESS WIRE)-- Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, announces the release of its 2025 Integrated Report.

The document presents Afya's trajectory throughout 2025, representing the Company's best operational performance since IPO, and marks the full adoption of the Integrated Reporting framework, providing an integrated view of the Company's performance, strategy, and value creation. This edition also includes a new chapter on technology and Artificial Intelligence, outlining how Afya is integrating AI into its medical education and healthcare solutions through dedicated governance and selected applications that support quality, reliability and scalability across the business.

The report further highlights Afya’s academic model and provides updates on environmental, social and governance (ESG) performance and risk management, including a second consecutive year of performance above the targets under the Company’s sustainability-linked loan with the International Finance Corporation (IFC), and the integration of climate-related risks into the Enterprise Risk Management (ERM) model.

Afya's 2025 Integrated Report is available at: https://ir.afya.com.br/annual-report/

About Afya Limited (Nasdaq: AFYA, B3: A2FY34)

Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610239947/en/

Investor Relations Contact:
Afya Limited
[email protected]

Source: Afya Limited

You May Also Be Interested In

• OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
• Saudi Arabia to Host Second Consultative Meeting for the 11th World Water Forum
• Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting